Lemmiwinks Friday, 11/29/19 11:35:53 PM Re: crowin post# 230899 Post # of 243203 Ps...on this board...CHERRY is a study...not a poster. And the WSJ article that will be written is for real..(either mega drug poney going it alone or more likely AMRN aqcuired by Pfizer or GILD).......Did a little shrimping in my time. Remember you from that past life......AMRN is the real deal. Ya can bank on it. Good luck. And it’s not even close to too late....but we already have a Captain and a Mrs. Captain....his message is AMRN good...Beer good....repeats it every Friday. Just read Re-ducit article and review the ADCOM panel transcript from 11/14/19....the Jeffries report on AMRN by Jeff Yee is what I believe is closest to the truth among all the analysts reports albeit....very conservative on its peak sales projection. Ya read these three things....you will be up to speed. Right now we all waiting on the PDUFA label....anytime between now and 12/28/19. Plus health Canada before the end of December. AMRN appears to be posting for the 400 more sales reps in US wich could be a go it alone play or a negotiating tactic for the BO. Many believe a tender offer is being discussed....just contingent on the expanded label so peak sales can be estimated....it’s wide open still....but I’m banking on $45 share either way...just the GIA is gonna be slower. Lastly there is a likely generic patent trial for January....could get settlement news in mid December or trial in January. So far looks to be strongly in AMRNs favor either way but settlement would be nicer as long as a buy out....trial win better for GIA....My prediction is wide label and $55/share BO. Others have other feelings. Again....if ya pull the trigger, good luck to you and welcome aboard. Lemmi- Also, there some really sharp dudes and duddettes on this board....both bears and bulls. Excellent reading all around. Enjoy.